阿托吉泮用于常规口服预防治疗失败的成人发作性偏头痛的预防治疗的安全性和有效性(ELEVATE):一项随机、安慰剂对照的3b期试验
ELEVATE是一项在13个国家73个中心开展的随机、双盲、安慰剂对照、平行组3b期试验,纳入315例既往2至4类常规口服预防药物失败的发作性偏头痛成人,随机接受阿托吉泮60 mg每日一次或安慰剂治疗12周。在意向治疗人群(OTHE,n=309)中,阿托吉泮组月偏头痛天数较基线变化为-4.2天,安慰剂组为-1.9天,组间差异为-2.4天(95%CI -3.2至-1.5;校正P<0.0001),常见不良事件为便秘(阿托吉泮组10% vs 安慰剂组3%)。
要点
- 在2至4类常规口服预防药物失败的发作性偏头痛成人中,阿托吉泮60 mg每日一次治疗12周可显著减少月偏头痛天数。
- 阿托吉泮组月偏头痛天数较基线变化为-4.2天,安慰剂组为-1.9天,组间差异为-2.4天(95%CI -3.2至-1.5;校正P<0.0001)。
- 阿托吉泮组最常见治疗中出现的不良事件为便秘(10% vs 安慰剂组3%),严重不良事件发生率为3% vs 0%。
核心结论
- 在既往2至4类常规口服预防治疗失败的发作性偏头痛患者中,阿托吉泮60 mg每日一次治疗12周安全、耐受良好,且较安慰剂显著且具有临床意义地减少月偏头痛天数。
- 阿托吉泮可能成为该难治人群的有效预防治疗选择。
研究设计与样本
- ELEVATE是一项在加拿大、捷克共和国、丹麦、法国、德国、匈牙利、意大利、荷兰、波兰、俄罗斯、西班牙、英国和美国共73个中心开展的随机、双盲、安慰剂对照、平行组3b期试验。
- 纳入18至80岁、既往2至4类常规口服偏头痛预防治疗失败的发作性偏头痛成人,按1:1随机分配至口服阿托吉泮60 mg每日一次或安慰剂,按基线月偏头痛天数、既往失败治疗类别数和地区分层。
- 主要终点为12周治疗期间月偏头痛天数较基线的变化,在off-treatment假设估计(OTHE)人群中分析,该人群包括安全性人群(至少接受1剂研究干预)中基线期和至少一个4周基线后期间有可评估数据的参与者。
- 主要终点采用重复测量混合模型分析,并使用固定序列程序控制多重比较。
- 试验注册于ClinicalTrials.gov(NCT04740827)和EudraCT(2019-003448-58),已完成。
主要发现
- 2021年3月5日至2022年8月4日期间,筛查540例,随机分配315例,313例(280例[89%]女性、33例[11%]男性、300例[96%]白人)至少接受1剂研究干预。
- OTHE人群共309例(安慰剂组155例,阿托吉泮组154例),12周期间月偏头痛天数较基线的最小二乘均值变化为安慰剂组-1.9(SE 0.4)天 vs 阿托吉泮组-4.2(SE 0.4)天,最小二乘均值差异-2.4天(95%CI -3.2至-1.5;校正P<0.0001)。
- 阿托吉泮组最常见治疗中出现的不良事件为便秘,156例中16例(10%) vs 安慰剂组157例中4例(3%)。
- 严重不良事件在阿托吉泮组156例中4例(3%) vs 安慰剂组0例;导致治疗中止的治疗中出现不良事件在阿托吉泮组3例(2%) vs 安慰剂组2例(1%)。
关键数值与推荐
- 阿托吉泮60 mg每日一次口服。
- 主要终点为12周治疗期间月偏头痛天数较基线的变化,在OTHE人群中分析。
- 月偏头痛天数较基线最小二乘均值变化:阿托吉泮组-4.2(SE 0.4)天 vs 安慰剂组-1.9(SE 0.4)天,最小二乘均值差异-2.4天(95%CI -3.2至-1.5;校正P<0.0001)。
- 便秘:阿托吉泮组156例中16例(10%) vs 安慰剂组157例中4例(3%)。
- 严重不良事件:阿托吉泮组156例中4例(3%) vs 安慰剂组0例;导致治疗中止的治疗中出现不良事件:阿托吉泮组3例(2%) vs 安慰剂组2例(1%)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为,阿托吉泮可能成为既往2至4类常规口服预防治疗失败的发作性偏头痛患者的有效预防治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atogepant, an oral calcitonin gene-related peptide receptor antagonist, has been approved for the preventive treatment of migraine, but its efficacy and safety in people who have been failed by conventional oral preventive migraine treatments has not yet been evaluated in a dedicated clinical trial. The ELEVATE trial evaluated the safety, tolerability, and efficacy of atogepant for the preventive treatment of episodic migraine in participants for whom two to four classes of conventional oral preventive treatments have failed. METHODS: ELEVATE was a randomised, double-blind, placebo-controlled, parallel-group, phase 3b trial done at 73 sites in Canada, the Czech Republic, Denmark, France, Germany, Hungary, Italy, the Netherlands, Poland, Russia, Spain, the UK, and the USA. Adults (18-80 years) with episodic migraine who had previously been failed by two to four classes of conventional oral treatments for migraine prevention were randomly assigned (1:1) using interactive web response technology to oral atogepant 60 mg once a day or placebo, stratified by baseline monthly migraine days, number of treatment classes participants have been failed by, and region. The primary endpoint was change from baseline in mean monthly migraine days across the 12-week treatment period in the off-treatment hypothetical estimand (OTHE) population, which included participants in the safety population (all participants who received ≥1 dose of study intervention) who had evaluable data available for the baseline period and for one or more of the 4-week post-baseline periods (whether on treatment or off treatment). The primary endpoint was analysed using a mixed model for repeated measures and a fixed-sequence procedure was used to control for multiple comparisons. The trial is registered with ClinicalTrials.gov (NCT04740827) and EudraCT (2019-003448-58), and is completed. FINDINGS: Between March 5, 2021, and Aug 4, 2022, 540 participants were screened, 315 were randomly assigned, and 313 participants (280 [89%] female, 33 [11%] male, and 300 [96%] White) received at least one dose of study intervention. In the OTHE population, which comprised 309 participants (155 assigned to placebo and 154 to atogepant), least squares mean changes from baseline in monthly migraine days across 12 weeks were -1·9 (SE 0·4) with placebo and -4·2 (0·4) with atogepant (least squares mean difference -2·4, 95% CI -3·2 to -1·5; adjusted p<0·0001). The most common treatment-emergent adverse event with atogepant was constipation in 16 (10%) of 156 participants (vs four [3%] of 157 for placebo). Serious adverse events occurred in four [3%] of 156 participants in the atogepant group vs none in the placebo group, and treatment-emergent adverse events resulting in treatment discontinuation occurred in three [2%] in the atogepant group vs two [1%] in the placebo group. INTERPRETATION: Atogepant 60 mg once a day was safe, well tolerated, and showed significant and clinically relevant reductions in mean monthly migraine days compared with placebo across 12 weeks in patients with episodic migraine who had previously been failed by two to four classes of conventional oral preventive treatments. Atogepant might be an effective preventive treatment option for patients in this difficult-to-treat population. FUNDING: Allergan (now AbbVie).
引用
- Tassorelli C, Nagy K, Pozo-Rosich P, et al. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol. 2024. PMID: 38364831. doi:10.1016/S1474-4422(24)00025-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。